

Published in final edited form as:

*Mol Microbiol.* 2013 May ; 88(4): 713–727. doi:10.1111/mmi.12216.

## Allergen 1 Regulates Polysaccharide Structure in *Cryptococcus neoformans*

Neena Jain<sup>1,2,\*</sup>, Radames J.B. Cordero<sup>1,\*</sup>, Arturo Casadevall<sup>1,2</sup>, and Bettina C. Fries<sup>1,2,#</sup>

<sup>1</sup>Department of Microbiology and Immunology, Albert Einstein College of Medicine of Yeshiva University, 1300 Morris Park Avenue, Bronx, New York 10461

<sup>2</sup>Department of Medicine (Division of Infectious Diseases), Albert Einstein College of Medicine of Yeshiva University, 1300 Morris Park Avenue, Bronx, New York 10461

### Abstract

*Cryptococcus neoformans* is an important human, fungal pathogen that sheds polysaccharide (exo-PS) into host tissues. While shed exo-PS mediates numerous untoward effects (including promoting increased intracranial pressure), little is known about the regulation of this phenomenon. Since down-regulation of the Allergen 1 (*ALL1*) gene is associated with high ICP, we investigated the relationship between *ALL1* expression and exo-PS structure using a variety of biophysical techniques. The  $\Delta all1$  mutants of two serotypes produced a shorter exo-PS with less branching and structural complexity than the parental strains. Consistent with lower branching, these exo-PSs manifested higher intrinsic viscosity than the parental strains. The  $\Delta all1$  mutant strains manifested differences in epitope expression and significant resistance to phagocytosis. Exo-PS of  $\Delta all1$  mutant exhibited anti-phagocytic properties. Comparative transcriptome analysis of mutant and parental strain under iron-deprived conditions indicated a role of *ALL1* in iron homeostasis, characterized by differential regulation of genes that mediate iron reduction and transport. Together, our results demonstrate a role of *ALL1* in regulating conformational aspects of PS structure and iron homeostasis. These findings provide a mechanism to explain how changes in *ALL1* expression influence virulence of switch variants and suggest that structural changes and polymer length are epigenetically regulated.

### Keywords

*Cryptococcus neoformans*; GXM; allergen 1; polysaccharide structure; branching

### INTRODUCTION

*C. neoformans* is an important fungal pathogen in patients with AIDS. The most common clinical presentation of cryptococcosis is chronic meningoencephalitis (CME), a leading infectious cause of death in the world, particularly in Africa (Park *et al.*, 2009), with 10-week mortality rates between 25–50% (Bicanic *et al.*, 2007; Imwidthaya and Pongvarin, 2000; Kambugu *et al.*, 2008). One of the unique features of *C. neoformans* is its PS capsule that is induced during infection (Zaragoza *et al.*, 2009). The PS capsule is essential for virulence (Chang and Kwon-Chung, 1994; McClelland *et al.*, 2005) and is predominantly composed of glucuronoxylomannan (GXM) (McFadden *et al.*, 2006). This large polymer consists of structural reporter groups (SRGs), which are composed of an  $\alpha$ -(1,3)-mannan

#Address correspondence to: Bettina C. Fries, M.D. Tel: 718-430-2365. Fax: 718-430-8968. bettina.fries@einstein.yu.edu.

\*Authors contributed equally to this work

main chain with  $\beta$ -(1,2)-glucuronic acid and a  $\beta$ -(1,2)- or  $\beta$ (1,4) xylosyl residues units (Cherniak *et al.*, 1998).

*C. neoformans* induces its polysaccharide capsule in iron deprived conditions and releases substantial quantities of exo-PS into the cerebrospinal fluid (CSF) during chronic infection causing serious complications (Goldman *et al.*, 1997; Graybill *et al.*, 2000). The accumulation of shed exo-PS in host tissues interferes with CSF re-absorption at the level of the granulations in the arachnoid villi and thus is thought to play a key role in the development of elevated ICP, (Graybill *et al.*, 2000). High ICP is difficult to treat, and is associated with significant morbidity and mortality in patients with CME (Dromer *et al.*, 2007; Graybill *et al.*, 2000; Seaton *et al.*, 1996). In patients with CME (Bicanic *et al.*, 2007; Bicanic *et al.*, 2008) a high CSF fungal burden correlates with increased ICP before and after fungal therapy. Nonetheless, a high fungal burden does not appear to be sufficient to produce elevated ICP (Bicanic *et al.*, 2009), suggesting that strain-related properties of exo-PS affect the development of high ICP.

Our previous studies using phenotypic switch variants support a role for exo-PS differences in promoting elevated ICP. In these studies we found that phenotypic switching from RC2-SM to a RC2-MC variant was associated with the shedding of an altered exo-PS, which caused elevated ICP and rapidly fatal CME in rats (Fries *et al.*, 2005). NMR analysis confirmed serotype D predicted SRG composition in RC2-SM and RC2-MC derived exo-PS. Static light scattering (SLS) analysis, demonstrated that the radius of gyration ( $R_g$ ) differed in RC2-SM and RC2-MC exo-PS despite comparable molecular mass ( $M_w$ ) and thus suggested that yet undefined macromolecular properties of the exo-PS were altered by phenotypic switching (McFadden *et al.*, 2007).

Phenotypic switching of RC2-SM to RC2-MC is associated with down-regulation of a defined set of genes, in particular Allergen1 (*ALL1*) (Jain *et al.*, 2009b). *ALL1* down-regulation is noteworthy as null mutant ( $\Delta all1$ ) mimics the hypervirulence of the RC2-MC switch variant including the strain's propensity to cause high ICP and premature death in rats (Jain *et al.*, 2009b). This is analogous to the pathogenesis of human CME with poor outcome.

In the present study, we used viscosity, SLS and dynamic light scattering (DLS) analysis to investigate the macromolecular properties of exo-PS that are shed in  $\Delta all1$  mutants of serotype A and D strains as well as their respective parental and reconstituted strains. The results obtained imply that the structure of shed exo-PS is greatly affected by the loss of *ALL1* function and phenotypic switching. Analysis of mass density, shape factor and viscosity, consistently demonstrate that changes of RC2-MC exo-PS are mediated by loss of *ALL1*. Specifically,  $\Delta all1$  strains produce a more viscous and smaller exo-PS with a lower degree of branching. In addition, microarray analysis of  $\Delta all1$  mutant in serotype D strain RC2 (RC2- $\Delta all1$ ) versus wild type (wt) of RC2 in minimal medium identified up-regulation of genes encoding cell surface reductases, iron permease/ferroxidase, cytokine inducing proteins and siderophore transporters. The impact and correlations of this structural variation and its association with iron homeostasis and pathogenesis of CME are discussed. We propose that biophysical characteristics of the exo-PS constitute emerging properties that are regulated and can be changed by phenotypic switching.

## RESULTS

### Null Mutants of *ALL1* ( $\Delta all1$ ) in the Serotype A and D Strains Exhibited Impaired Capsule Induction and Shed a More Viscous PS

Previous work demonstrated that RC2- $\Delta all1$  exhibited subtle changes in capsule size and impaired capsule induction (Jain *et al.*, 2009b). We sought to establish whether these changes were also present in the serotype A strain background and generated a  $\Delta all1$  mutant in H99 reference strain (H99- $\Delta all1$ ). The baseline capsule diameter was not increased in H99- $\Delta all1$ , but impaired capsule induction was confirmed in H99- $\Delta all1$  *in vivo* (Fig 1A) and *in vitro* under various capsule-inducing conditions (Table S1). Capsule induction defects were corrected in reconstituted strains ( $\Delta all1 + ALL1$ ) and more pronounced induction was observed in the over expression mutant P<sub>CTR4-2</sub>-*ALL1* (Fig S1, Table S2), when *ALL1* was placed under a copper inducible promoter resulting in 23 fold over expression of *ALL1* (data not shown).

Next, we quantified the shedding of exo-PS for both serotypes by ELISA. RC2 and H99 shed different amounts of GXM and also H99 sheds GXM at a later time. Therefore, experiments measuring GXM shedding were designed for H99 and RC2 and their respective mutants at different times. Regardless, the exo-PS shedding was found to be higher in liquid culture for  $\Delta all1$  mutants of both serotypes (Fig 1C).

The intrinsic viscosities [ $\eta$ ] of exo-PS shed by  $\Delta all1$  mutants of H99 and RC2 were determined using a modified Ostwald-type capillary glass. Exo-PS derived from  $\Delta all1$  mutants in both serotypes (A and D) consistently exhibited higher viscosity, when compared to exo-PS derived from the respective parental wt and reconstituted strain (Fig 1D). The increased viscosity of the RC2- $\Delta all1$  derived exo-PS was comparable to that of the RC2-MC derived exo-PS, which is the phenotypic switch variant of RC2-SM (RC2-wt) that exhibits down-regulation of *ALL1* gene transcripts (Jain *et al.*, 2009b).

### Loss of *ALL1* in H99 confers a hypervirulent phenotype similar to RC2- $\Delta all1$

In the murine intratracheal (i.t.) infection model, hypervirulence of H99- $\Delta all1$  relative to the H99-wt was documented analogous to the RC2- $\Delta all1$  mutant (Fig 1B). The median survival of animals infected with high inoculum ( $10^6$ ) with H99- $\Delta all1$  and H99-wt was 15 d vs 21 d ( $p = 0.04$ ). At lower infection inoculum ( $10^5$ ), the H99-wt was successfully cleared from lung tissue at 10 days ( $< \text{CFU log } 2.3 \pm 0.34$  per lung) whereas the H99- $\Delta all1$  was not ( $\text{log } 6.4 \pm 0.5$  for,  $p = 0.01$ ). Doubling times of mutant and wt were comparable confirming that enhanced virulence is not merely due to growth differences but rather altered host-pathogen interaction.

### Loss of Allergen1 Altered PS Macro-structural Properties

Next, we pursued systematic analysis of the exo-PSs by both SLS and DLS analysis. All exo-PS solutions exhibited significant but comparable polydispersity, which was expected, based on prior studies (Cordero *et al.*, 2011) (Fig 2). SLS yielded consistent differences in  $M_w$  and  $R_g$  (Table 1). A 2- to 5-fold decrease in PS  $M_w$ ,  $R_g$  and hydrodynamic radius ( $R_h$ ) was observed for  $\Delta all1$  strains in both serotype backgrounds. Changes in  $R_h$ , which reflects the apparent size of the molecules in solution, were more pronounced than changes in  $R_g$  (Table 1), suggesting differences in PS conformation. Combining data from SLS and DLS further assessed structural conformation of exo-PS molecules in solution (Burchard *et al.*, 1980). The mass density, which is the ratio between the  $M_w$  of exo-PS and their  $R_g$ , and the shape factor, which represents the ratio of  $R_g$  and  $R_h$ , were calculated for all exo-PS. These parameters indicated the occurrence of significant *ALL1*-dependent structural variation in shed exo-PS. A conserved decrease in mass density and increase in shape factor (1.6- and

4.6-fold, respectively) was evident upon loss of *ALL1* (Table 1). Most importantly, most measured differences including the polymer size difference reverted to wt values in the reconstituted strains (Fig 2). In addition, differences were consistent for both  $\Delta all1$  strains although the SRGs of serotype D and serotype A strains differ by a single xylose residue. In summary, DLS and SLS data confirm that  $\Delta all1$  mutant exo-PS are less branched and have a lower mass density compared with exo-PS from the parental wt strains. These data were consistent with the observed increased viscosity in  $\Delta all1$  mutants.

### Loss of *ALL1* Produces PS Molecules with Differences in Antibody Reactivity

Given the conformational differences in the exo-PS, we studied the binding ability of a panel of anti-GXM monoclonal antibodies (mAb) that recognize distinct epitopes on the polysaccharide capsule. These mAbs yield defined staining patterns that correlate with specific serotype specific SRGs (Belay *et al.*, 1997). Previous work documented that binding of mAbs can be greatly influenced by the degree of PS branching and conformation (Cordero *et al.*, 2011). A decrease in mAb 13F1 and 21D2 binding was observed for exo-PS isolated from the H99- $\Delta all1$  (Fig 3A) by ELISA. Binding differences were also documented with mAb 12A1 for RC2-wt and RC2- $\Delta all1$  derived exo-PS by ELISA and also on capsules of live yeast cells as evident by capsular staining (Fig 3B).

No differences were evident for binding of mAb 18B7, however, 18B7-mediated phagocytosis was reduced for mutants in both genetic backgrounds (Fig S2). Consistent with structural differences in the PS capsule, we also observed a significant decrease in complement-mediated phagocytosis of  $\Delta all1$  cells by J774 macrophage-like cells (Fig 3C) in both serotypes. In addition, when exo-PS secreted by wt,  $\Delta all1$  and  $\Delta all1 + ALL1$  was added to respective wt cells in both serotypes, we documented that  $\Delta all1$  exo-PS inhibited complement mediated phagocytosis more effectively than wt-exo-PS and  $\Delta all1 + ALL1$  exo-PS (Fig 3D).

### Gene regulation in $\Delta all1$ under different growth conditions

To further elicit gene function of *ALL1*, a transcriptome analysis of RC2- $\Delta all1$  vs. RC2-wt was performed. For microarray experiments, RC2-wt and RC2- $\Delta all1$  cells were grown in minimal medium, and Yeast Extract Peptone Dextrose medium (YPD) overnight at 37°C, diluted 1:100 into fresh medium and grown overnight up to an OD<sub>600nm</sub> of 0.6 at 37°C with agitation at 150 rpm. Microarray analysis demonstrated differential regulation of genes with very little overlap between the two growth conditions (Table S3). A total of 15 and 271 genes were found to be down regulated, 2 fold or more in RC2- $\Delta all1$  when grown in minimal media and YPD, respectively. In minimal media up-regulation of 111 genes (2 fold) was observed in  $\Delta all1$ , which includes a set of genes related to iron transport and homeostasis [e.g. cell surface reductase (*FRE1*), a high affinity iron permeases gene (*FTR1*), a metalloredutase, and siderophore transporters (Jung *et al.*, 2006) Table 2], The most abundantly up-regulated gene in the RC2- $\Delta all1$  cells was *CIG1* (19.7 fold), which encodes a mannoprotein involved in the retention of iron at the cell surface and/or in the uptake of siderophore-bound iron. It affects growth in low-iron medium, and alters capsule response to iron-replete conditions (Lian *et al.*, 2005). This up-regulation was only observed in minimal media, which was also the growth condition for exo-PS isolations. In YPD, loss of *ALL1* resulted in the up-regulation of approximately 270 genes, which were related to multiple cellular pathways. We further analyzed the data for gene ontology (GO) categories for the biological processes of differentially expressed genes in minimal media. The analysis indicates that differentially expressed genes were significantly enriched with GO categories related to oxidoreductase activity, oxidation-reduction process and transmembrane transport after loss of *ALL1* (Table 3). Differentially regulated genes with GO term related to oxidoreductase activity were genes related to reductive iron uptake systems such as *FRE1*,

Ferric-chelate reductases (CNG00110), metalloreductase (CNG00950) and Cytochrome-b5 reductase (CNB02540). The other highly ranked group, transmembrane transport also included 4 iron related transmembrane transporters, namely *FTR1*, CNM02430, CNG00120 and CNB00400. In addition, the drug transporter (CNJ00070) was 7- fold up-regulated in  $\Delta all1$ . The hexose transport related protein (CNE02910), and the carboxylic-acid transport protein (CNJ01360) were also up-regulated whereas the sugar transporter (CNH00490) was down-regulated. Genes classified under “integral to membrane” were also ranked in the analysis but did not reach significance (Table S3). Differential expression of iron transporters and siderophores were further confirmed by Real time PCR on RC2 (Fig 4A) and H99 (Fig 4B). Real time PCR confirmed the signature of up-regulated iron-transport genes in  $\Delta all1$  mutants in both serotypes, albeit difference were found among the serotypes and also minor differences in fold regulation with respect to the microarray analysis. It is noteworthy that these genes were not differentially regulated in microarrays done in YPD or sabouraud dextrose medium (Jain *et al.*, 2009b), suggesting that *ALL1* negatively controls iron homeostasis only under starvation conditions. A role of *ALL1* in iron regulation was further supported, by demonstrating accumulation of intracellular iron under low-iron conditions (Fig 5A & 5B). Enhanced iron accumulation was not documented in the presence of iron (Fig 5C & 5D). Growth rate of wt and  $\Delta all1$  was slow but comparable in low iron medium (data not shown). Additionally, sugar transporter (CNH00490) was down-regulated under all growth conditions. In summary, comparative transcriptional profiling supports a role of *ALL1* in iron homeostasis under limited nutrition and iron conditions and a role in regulating sugar transport, which could affect production of capsular polysaccharide.

#### **$\Delta all1$ mutant exo-PS assists or activates the iron homeostasis related genes expression**

Next, we tested the effect of exo-PS derived from the  $\Delta all1$  mutant on expression of iron transport related genes. H99-wt and H99- $\Delta all1$  cells were grown in minimal media for 16h supplemented with 40 $\mu$ g/ml exo-PS of H99- $\Delta all1$  and H99-wt respectively at 37°C with agitation at 150 rpm. Transcript levels of selected genes related to iron homeostasis were quantified by real time PCR. Addition of H99- $\Delta all1$  exo-PS in H99-wt cells resulted in up-regulation of *FTR1*, *FRE1*, CNM02430, CNM02420, CNH01230, CNG00950, *CIG1*, and CNB00400 transcripts (Fig 5E, white bars). Up-regulation was also seen if the mutant exo-PS was added to mutant cells (Fig 5E, Black bars). Interestingly, addition of H99-wt exo-PS to H99- $\Delta all1$  cells resulted in down-regulation of iron transport associated genes (Fig 5E, crossed lines bars). Consistent with our expectation, transcript levels of the sugar transporter were not affected by the addition of exo-PS.

## **DISCUSSION**

Here we report that structural characteristics of shed cryptococcal PS are regulated by *ALL1* expression, a gene that is regulated *in vivo* during chronic infection. This result is important because it provides a mechanism by which *ALL1* can modulate the virulence of *C. neoformans*. Biophysical alterations of the exo-PS affect clinically relevant characteristics of the polymers such as their viscosity, mAb reactivity, and complement-mediated phagocytosis. *In vivo*, these altered polymers affect capsule induction and the propensity of the mutants to cause high ICP in rats (Jain *et al.*, 2009b). In addition, we demonstrate that loss of *ALL1* up-regulates iron transport resulting in enhanced accumulation of intracellular iron. Our results link the presence of high ICP in  $\Delta all1$  infected rats, to impaired capsule induction and *in vivo* shedding of shorter and less branched PS polymers that exhibit significantly higher viscosity when compared to the wt polymers. Hence, this work associates the modulation of a gene that is regulated *in vivo* with the most catastrophic complication of cryptococcal CME through the production of a structurally different exo-PS. These results also further support a link between exo-PS and iron regulation possibly

through altered binding and sensing of extracellular iron level, which then indirectly regulates expression of iron transport and iron reduction pathway associated genes.

Cryptococcal PSs are complex polymers that have distinct physical and chemical properties reflected by their molecular mass, shape, and composition. Previous studies have shown that polymer diameter does not vary significantly as a function of SRG composition, but is more affected by secondary and tertiary structure of the molecule (McFadden *et al.*, 2007). Consistent with this finding, SRG type does not correlate with clinical presentation or outcome of CME in a consistent matter (Cordero *et al.*, 2011). Yet, macromolecular properties such as molecular mass and hydrodynamic size and/or shape have shown to underlie GXM biological functions or reactivity (Cordero *et al.*, 2011; Fonseca *et al.*, 2010). The view that GXM molecules are linear polymers (Doering, 2009) was recently revised and it was shown that degree of PS branching and higher order structural characteristics could be modulated by the dextrose concentration of the medium in which *C. neoformans* was cultured (Cordero *et al.*, 2011; Guimaraes *et al.*, 2010). We investigated exo-PS from mutants (RC2- $\Delta all1$  & H99- $\Delta all1$ ) and parental (RC2 & H99) strains that have previously been well characterized with respect to their virulence and relative ability to elicit high ICP in rats (Jain *et al.*, 2009b). Raised ICP is a major and commonly fatal complication in patients with cryptococcal CME and is not necessarily responsive to antifungal therapy. Although the presence of high GXM titers are necessary to cause high ICP, they are not sufficient as there are patients with high crypt-Ag titers that do not develop high ICP (Bicanic *et al.*, 2009).

GXM are large heterodisperse polymers (> 1 mDa) and cannot be studied by NMR or crystallography. However, LS provides the means to gain insight into their shape. LS analysis showed that exo-PS polymers from  $\Delta all1$  mutants are shorter, and consequently exhibit less mass density. Exo-PS from mutants generated in both the serotype D and A strain backgrounds exhibited consistently these length and mass changes, although GXM polymers from serotype D and A strains are composed of distinct SRGs that can be distinguished by NMR. Shorter length of polymer is corrected to wt length in the reconstituted  $all1 + ALL1$  mutants of RC2 and H99. In addition when the gene is over expressed capsule induction is even more pronounced. This finding further supports our conclusion that *ALL1* regulates length of the GXM-polymer either directly or indirectly. The finding of shorter polymers with smaller masses was consistent with the impaired capsule induction of both  $\Delta all1$  mutants in host tissue and *in vitro* (Jain *et al.*, 2009b). Our data substantiate previous conclusions that the longest GXM polymers span the entire diameter of the capsule (Frases *et al.*, 2009) and support the notion that larger PS capsules shed larger exo-PSs.

Transcriptome analysis in minimal medium conditions unexpectedly demonstrated up-regulation of genes involved in iron homeostasis including iron transporters and reductases. This signature was confirmed by real time PCR and is consistent with data from the GO analysis. *CIG* gene was the most abundantly up-regulated transcript by real time PCR in H99 and by microarray in RC2. Why it RT PCR yielded a lower up regulation in RC2 is not clear because the growth conditions were exactly the same for both assays. Consistent with the observed transcript profile, both  $\Delta all1$  mutants accumulate more iron intracellularly under low-iron conditions. Co-cultivation of wt and mutant cells with wt and mutant exo-PS indicates that 9 of 13 iron related genes tested are up-regulated, when mutant-exo-PS is added to wt cells and down-regulated when wt-exo-PS is added to mutant cells. This observation further indicates that there is indeed a link between exo-PS and iron transport. One possible explanation is that mutant exo-PS binds more iron resulting in up-regulation of genes associated with iron sensing and transport. In the CSF, iron levels are low and the pathogen must compete with the host for iron and thus enhanced iron availability can

exacerbate the outcome of cryptococcal CME (Barluzzi *et al.*, 2002). Based on our findings we hypothesize that down-regulation of *ALL1* does not only affect the polysaccharide capsule but may also render the pathogen more fit in an iron depleted host environment.

A complex regulatory network composed of distinct but partially overlapping pathways, regulates capsule induction. Others have shown that 316 genes are positively regulated during capsule induction, including *ALL1* (Haynes *et al.*, 2011). This network includes the cAMP pathway, which activates Pka1 and then Nrg1, which regulates genes directly involved in capsule assembly. An important pathway of capsule regulation involves iron homeostasis *Hap3*, *Hap5*, and *Hapx* (Jung *et al.*, 2010) as well as the iron sensing transcription factor *CIR1* (Jung *et al.*, 2006). Review of previously published microarray data revealed that *ALL1* was not differentially regulated under low iron conditions, however 5 and 3 fold down-regulated in  $\Delta cir1$  mutant under low and high iron conditions, (Jung *et al.*, 2006). *ALL1* was also significantly up-regulated in  $\Delta hapx$  under low and high iron conditions (FeCl<sub>3</sub> and transferrin) and was also up-regulated in  $\Delta hap3$  mutant in response to transferrin (Jung *et al.*, 2010). One gene that was not related to iron transport but nevertheless highly regulated in the mutant was a gene that encodes a multidrug resistance transporter (DHA1 family) (CNJ00070). Interestingly, in *Saccharomyces cerevisiae* this transporter is up-regulated in cells exhibiting reduced susceptibility to azoles (Barker *et al.*, 2003).

Importantly, deletion of *ALL1* gene affects baseline capsule size in RC2. So far, the phenotype of impaired capsule induction has only been described for  $\Delta all1$  mutants. Here we document that loss of *ALL1* results in the secretion of more exo-PS molecules with higher viscosity and smaller size and lower degree of branching. Several studies have indicated in the past that GXM polymer length is dynamic. Yoneda *et al.* showed that exo-PS shed early in the course of *in vitro* growth exhibited smaller molecular sizes when compared to exo-PS shed after 72 h (Yoneda and Doering, 2008). Frases *et al.* demonstrated that the capsule associated GXM was significantly different from shed exo-PS and that the diameter of the capsular PS and the exo-PS correlated (Frases *et al.*, 2008). Finally, Cordero *et al.* showed that increasing dextrose in culture medium decreased polymer length and branching, which again resulted in structural differences (Cordero *et al.*, 2011).

How and in what sub-cellular compartment the length of PS polymers are determined is not understood. It is also not clear if iron is specifically required in that process or important as a sensor only. *ALL1* is regulated by *SPI* in stress-associated pathways (Adler *et al.*, 2011) as well as during capsule induction (Haynes *et al.*, 2011). In contrast to bacterial PSs, GXM is a heteropolymer and magnitude larger in size, thus its assembly process is very different (Zaragoza *et al.*, 2009). Current thinking is that the cryptococcal GXM polymers are pre-assembled in lipid associated cytoplasmic structures (Oliveira *et al.*, 2009) and exported across the cell wall in vesicles (Rodrigues *et al.*, 2007). All1p is a cytoplasmic protein, which is not present in vesicles (Jain *et al.*, 2009b; Rodrigues *et al.*, 2008) but loss of this protein down-regulates a sugar transporter (CNH00490). We therefore hypothesize that All1p is indirectly involved in GXM assembly, as its only homologues are found in non-encapsulated fungi that infect plants.

In the phenotypic switch variant RC2-MC hydrodynamic diameter and  $R_g$  differ from that of the RC2- $\Delta all1$  mutant, however shape factor, and viscosity are similarly altered consistent with the presence of high ICP in RC2-MC infected rats. Several studies demonstrate that structural changes alter the biological effects of GXM, which is a potent immunomodulator. For instance, the hydrodynamic effective diameter of the GXM molecules correlated with their ability to stimulate cellular responses (Fonseca *et al.*, 2010) and affects the binding of monoclonal antibodies (Frases *et al.*, 2008; Nimrichter *et al.*, 2007).

Studies on *in vivo* derived *C. neoformans* cells further supported the notion that PS structure affects Ab and complement binding and demonstrated that the spatial deposition of C3 within the capsular matrix was influenced by the density of the capsular matrix (Gates and Kozel, 2006). Charlier et al. showed that brain invasion by *C. neoformans* was associated with changes in cryptococcal capsule structure and altered binding of PS specific mAbs (Charlier et al., 2005). Our data now links structural changes to loss of *ALL1*, which is down-regulated in the setting of phenotypic switching during chronic infection.

Older conclusions that impaired capsule induction is associated with loss of virulence (Granger et al., 1985) were not confirmed. In the rat model the altered exo-PS elicits high ICP resulting in rapid death and in the pulmonary model the altered exo-PS constitutes a potent immunomodulator and has dramatic effects on the host response especially macrophage activation and T-cell response (Guerrero and Fries, 2008; Guerrero et al., 2010; Jain et al., 2009a). Most importantly, the mutant elicits high ICP at a comparable fungal burden. Hence, hypervirulence is the consequence of altered host pathogen response to altered exo-PS, which results in increased fungal burden as the host response becomes ineffective.

We propose a model whereby loss of *ALL1* function in clinical *C. neoformans* strains will result in altered iron homeostasis that results in an ICP inducing hypervirulent strain, because GXM polymers with altered length and shape that are more viscous and cannot be cleared by the host are produced. The ability to alter polymer length is a trait that was most likely selected for survival in the environment where the fungus encounters amoeboid predators (Pirofski and Casadevall, 2008) and extreme climate conditions. This observation underscores the notion that pathoadaptation of *C. neoformans* to the mammalian host is not driven by a single virulence factor that is shut on or off but rather constitutes fine epigenetic regulation of sophisticated pathways.

## EXPERIMENTAL PROCEDURES

### Yeast strains and culture conditions

*C. neoformans* strains were cultivated in chemically defined minimal medium (10 mM MgSO<sub>4</sub>, 29.3 mM KH<sub>2</sub>PO<sub>4</sub>, 13 mM glycine, 3 μM thiamine-HCl, 15 mM glucose; pH 5.5) for exo-PS isolation, microarray and Real time PCR. For exo-PS isolation, microarray and Real time PCR, cells were grown overnight at 37°C, diluted 1:100 into fresh medium and grown overnight up to an OD<sub>600nm</sub> of 0.6 at 37°C with agitation at 150 rpm. Asparagine salt medium contains 1 g L<sup>-1</sup> asparagine, 10 mM sodium phosphate (pH 6.5), and 0.25 g L<sup>-1</sup> MgSO<sub>4</sub> and was used to grow *ALL1* overexpression strain, *P<sub>CTR4-2</sub>-ALL1*. Low iron medium was prepared as described elsewhere (Nyhus et al., 1997). For GXM isolation, RC2-wt and H99-wt and their respective mutants were cultured for 14 days and 21 days, respectively at 37°C under shaking in minimal medium. For screening mutants YPD agar supplemented with 100mg L<sup>-1</sup> nourseothricin (NAT) or 200mg L<sup>-1</sup> neomycin G418 (NEO) was used. The *C. neoformans* strains used in the study are listed in Table 4.

### Generation of *ALL1* mutant in H99

H99 reference sequence was accessed through Fungal Genome Initiative database at the Broad Institute ([http://www.broadinstitute.org/annotation/genome/cryptococcus\\_neoformans/MultiHome.html](http://www.broadinstitute.org/annotation/genome/cryptococcus_neoformans/MultiHome.html)). To generate gene disruption mutants H99-wt genomic DNA was isolated to amplify upstream and downstream regions of *ALL1* using primers listed in Table S4. The entire coding region of *ALL1* was replaced with a neomycin resistance marker (2098bp) by homologous recombination using standard procedure



described earlier (Jain *et al.*, 2009b). Homologous recombination was confirmed by PCR, southern blot analysis and transcription level of *ALL1* by real time PCR.

### Complementation of *ALL1* gene in H99 $\Delta all1$

The wt *ALL1* gene was amplified with the native promoter from the H99-wt genomic DNA with primers H99*ALL1*-RecF and H99*ALL1*-RecR (Table S4) and cloned into plasmid pJAF13. The plasmid was linearized using *ApaI* and introduced into H99- $\Delta all1$  cells by biolistic transformation. The *ALL1*-positive clones were selected on YPD agar containing 100mg L<sup>-1</sup> NAT (Werner Bioagents, Germany). Gene complementation was confirmed by PCR and transcription level of *ALL1* by real time PCR.

### Construction of *ALL1* Overexpression strain, $P_{CTR4-2}$ -*ALL1*

To construct RC2-SM strain overexpressing *ALL1*,  $P_{CTR4-2}$  promoter was amplified from plasmid pCTR4-2/Gust (Ory *et al.*, 2004) and fused with *ALL1* gene amplified from RC2-SM genomic DNA, in frame using restriction site *NdeI*. Flanking region of 1000bp upstream of *ALL1* including 5' UTR, Ori/Amp<sup>r</sup> and NEO cassette was excised from previously generated TA clones using *van9II* digestion to generate plasmid 5' UTR/NEO/ $P_{CTR4-2}$ -*ALL1*/Amp. The plasmid was used to amplify 5' UTR-NEO- $P_{CTR4-2}$ -*ALL1* using primers stated in Table S4 and biolistically transformed in RC2-SM. Standard procedure was further adapted to screen and confirm clones as mentioned above. To overexpress *ALL1*, the cells were grown in minimal medium or asparagine salt medium with 200 $\mu$ M of bathocuproinedisulfonic acid (BCS), copper chelator. Overexpression was confirmed via checking transcription levels by real time PCR.

### GXM isolation

Culture supernatants were separated from yeast cells by centrifugation at 6,000 g (20 min, 4°C). Supernatants were successively centrifuged and filtered through 0.45 $\mu$ m membranes. Supernatants were concentrated  $\cong$  20-fold using an Amicon ultrafiltration cell and regenerated cellulose 100 KDa, 76 mm ultrafiltration membrane (Millipore, Billerica, MA) with stirring. After concentration the fluid phase was discarded and the viscous film over the membrane was scraped carefully and lyophilized.

### Light Scattering Analysis

Average-molecular mass ( $M_w$ ) and radius of gyration ( $R_g$ ) were determined by multi-angle laser (static) light scattering (BI-MwA; Brookhaven Instruments Corp.), as described (Cordero *et al.*, 2011). Each PS sample was measured twice with good reproducibility. Average hydrodynamic radius ( $R_h$ ) of PS samples was determined by Dynamic light scattering using a 90 Plus Particle Sizing analyzer (Brookhaven Instruments Corp.), as described (Cordero *et al.*, 2011). Average  $R_h$  and multimodal size distributions were calculated from ten individual measurements.

### Viscosity

Intrinsic viscosity of the exo-PS samples isolated from H99 and RC2 and their respective mutants cultures supernatants were measured using a modified Ostwald-type capillary glass viscometer (Cannon-Manning Semi-Micro, Technical Glass Co. Dover, NJ) in a temperature-controlled water bath at 25°C, as previously described (Cordero *et al.*, 2011). Exo-PS samples were dissolved in ultrapure water and temperature-stabilized before measurements. Measurements were done in triplicate.

## GXM ELISA

ELISA were done as described previously (Casadevall *et al.*, 1992). Briefly, a 96-well polystyrene plate was coated with IgM (1 $\mu$ g/ml) at 4°C overnight. Unbound sites are blocked with 1% BSA for 2hrs at room temperature (RT). Anti-GXM mAb 2D10, 13F1 or 12A1 (100 $\mu$ l of 1 $\mu$ g/ml) was added to the plate and incubated for 1hr at RT. Wells were washed with TBS-T 3 times (3X) and incubated with isolated exo-PS [10–0.740nM, diluted in PBS (obtained by 1:3 serial dilutions vertically)] either from wt (SM, H99) or their respective  $\Delta all1$  mutant. After washed with TBS-T (3X), wells were incubated with 100 $\mu$ l of 1 $\mu$ g/ml mAb18B7 diluted in PBS ranging from 1–0.0000016  $\mu$ g/ml (obtained by 1:3 serial dilutions horizontally), followed by detection with 1:1000 dilution of anti-IgG<sub>1</sub>-AP antibody. All samples were done in triplicates and all incubations were done for 1h at 37°C. For GXM shed experiment, the supernatants were collected at days 1, 3, 6, 12, 21 of cultivation and ELISA was performed using above-mentioned procedure (used mAb 2D10) to quantitate GXM concentration.

## Complement mediated Phagocytosis Assay

Approximately  $2.5 \times 10^4$  J774 macrophage-like cells/well (ATCC) were plated in 96-well plates containing Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% (v/v) fetal bovine serum (FBS) at 37°C in a 5% CO<sub>2</sub> atmosphere and under the stimulation of recombinant murine  $\gamma$ -interferon and LPS; 100U/mL and 0.5  $\mu$ g/ml, respectively. *C. neoformans* cells were washed and suspended in DMEM supplemented with 20% mouse serum (Pel-Freez Biologicals, Rogers, AR) and added to macrophages to generate a ratio of 5 yeast cells per macrophage. For some experiments, 5  $\mu$ g of exo-PS from wt,  $\Delta all1$  and  $\Delta all1 + ALL1$  strains were added to the wt wells to test the inhibitory capacity of different PSs. Mixture was incubated at 37°C and 5% CO<sub>2</sub> for 2h. After incubation, wells were washed with PBS to remove non-adherent yeast cells. Cells were then fixed with ice-cold methanol for 30 min and stained with 1:5 solution of Giemsa stain in distilled water. The percentage of phagocytosis was determined by microscopic examination of macrophages with internalized *C. neoformans* cells divided by total macrophages. At least 300 macrophages cells were examined per well and each condition was done in triplicates.

## Animal Studies

Balb/c mice (Female, 6–8 weeks) were obtained from the National Cancer Institute (Bethesda, MD). Mice (n = 10 per group) were infected intratracheal (i.t) with  $10^6$  or  $10^5$  *C. neoformans* H99-wt, H99- $\Delta all1$  and H99  $\Delta all1 + ALL1$  cells that were grown overnight in SAB medium. Mice were observed on a daily basis for survival and sacrificed if they were moribund in accordance with IACUC regulations.

## RNA Purification and quantitative Real Time PCR Assays

For microarray, RC2-SM and RC2- $\Delta all1$  were grown in two different culture medium conditions including minimal media (same media which was used for exo-PS isolation) and YPD broth. Cells were grown for overnight, diluted 1:100 and then again grown overnight or up to an OD of 0.6–0.7 with agitation (150 rpm) at 37°C. Approximately,  $10^8$  cells were collected and mechanically disrupted by bead beating in RLT buffer (Qiagen) using 0.5mm zirconia beads for 1 min, for a total of 4 cycles with 2 min rest on ice in between cycles. Following lysis, total RNA was isolated using QIAGEN® RN easy mini kit, according to the manufacture's instructions. For real time PCR, RNA was further cleaned up for residual DNA using MessageClean Kit (genHunter corp.) and cDNA was synthesized using First strand superscript II RT kit (Life technologies) with 1 $\mu$ g total RNA according to manufacturer's instruction. RNA was also isolated from H99 and H99- $\Delta all1$ . Relative expression of selective genes was measured by real time PCR using power SYBR green

(applied biosystem) in ABI 384 system and primers listed in Table S4. Gene expression levels were normalized using the control gene  $\beta$ -actin. Primer efficiency was determined by serially diluting the cDNA and monitoring DNA amplification by real-time PCR. The relative transcript levels were determined using the delta-delta CT method.

To investigate the link between exo-PS structure and regulation of Iron- related genes, H99-wt and H99- $\Delta allI$  cells were grown for 16h in minimal media supplemented with 40 $\mu$ g/ml exo-PS of H99- $\Delta allI$  and H99-wt respectively. Specifically for control, H99-wt cells were grown with 40 $\mu$ g/ml exo-PS of H99-wt and H99- $\Delta allI$  cells were grown with H99- $\Delta allI$  exo-PS for 16h with shaking at, 37°C. Total RNA was isolated and real time PCR was done on 13 genes differentially expressed in microarray analysis related to iron-transport i.e., *FTR1*, *FRE1*, CNM02430, CNM02420, CNB02540, CNG00120, CNH01230, CNG00110, CNG00950, CNC01660, CNK02840, CNB00400, CNI01980 and  $\beta$ -actin as control. The mRNA levels were normalized against their respective  $\beta$ -actin and expression was calculated using the delta-delta CT method. The fold change was calculated as mRNA ratio.

### Microarray Hybridization

Experiments were performed in duplicate (Minimal Media arrays) or triplicate (YPD arrays). Total RNA hybridization and data acquisition were performed by the Genome technology access center, Washington University (<http://gtac.wustl.edu/services/microarray/rna-analysis/cryptococcus-neoformans.php>) according to their established protocols for *C. neoformans* microarrays. For analysis, raw data was imported in Partek genomic suite and intensity-dependent (LOESS) normalization was implemented in the software. Values for replicate probes on the array were averaged to represent the expression of the associated gene. Genes were considered for further evaluation if they showed a fold change of > 2.0.

### Gene Ontology (GO) Enrichment Analysis

For gene ontology enrichment, each gene was assigned GO category according to the Broad Institute's PFAM annotations using the mapping provided by the Gene Ontology project (<http://www.geneontology.org/external2go/pfam2go>). A hypergeometric test was applied for each GO category, the resulting p-values were corrected for multiple hypothesis testing, and a cutoff of 0.05 was used to determine significance.

### Determination of Cellular Iron Concentration

To determine intracellular iron concentration, the wt and the  $\Delta allI$  mutants were grown in minimal media overnight and subcultured in minimal media +100 $\mu$ M bathophenanthroline disulfonic acid (BPS), iron chelator for 16h to deplete intracellular iron stores. Cells were washed twice with iron free water and grown with or without 100 $\mu$ M FeCl<sub>3</sub> in low iron media for 16h. Cell cultures were washed three times with low-iron water and mixed with lysis buffer (50 mM HEPES-KOH pH 7.5, 140 mM NaCl, 1 mM EDTA and 1% Triton X-100) as described (Choi *et al.*, 2012). Cells were disrupted and homogenized using glass-beads in a bead beater for a total of 4 cycles with 2 min rest on ice in between cycles. Iron concentration of lysate was measured using the Abnova Iron assay kit according to the manufacturer's instruction. Tests were run in triplicates and each sample iron concentration was normalized against total protein concentration.

### Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

## Acknowledgments


This work was supported by NIH awards AI059681, AI033774, HL059842, and AI033142. RJBC was supported by the Training Program in Cellular and Molecular Biology and Genetics, T32 GM007491. We thank Dr. Goldman for critical reading of the manuscript.

## References

- Adler A, Park YD, Larsen P, Nagarajan V, Wollenberg K, Qiu J, Myers TG, Williamson PR. A novel specificity protein 1 (SP1)-like gene regulating protein kinase C-1 (Pkc1)-dependent cell wall integrity and virulence factors in *Cryptococcus neoformans*. *The Journal of biological chemistry*. 2011; 286:20977–20990. [PubMed: 21487010]
- Barker KS, Pearson MM, Rogers PD. Identification of genes differentially expressed in association with reduced azole susceptibility in *Saccharomyces cerevisiae*. *J Antimicrob Chemother*. 2003; 51:1131–1140. [PubMed: 12697649]
- Barluzzi R, Saleppico S, Nocentini A, Boelaert JR, Neglia R, Bistoni F, Blasi E. Iron overload exacerbates experimental meningoencephalitis by *Cryptococcus neoformans*. *J Neuroimmunol*. 2002; 132:140–146. [PubMed: 12417444]
- Belay T, Cherniak R, Kozel TR, Casadevall A. Reactivity patterns and epitope specificities of anti-*Cryptococcus neoformans* monoclonal antibodies by enzyme-linked immunosorbent assay and dot enzyme assay. *Infect Immun*. 1997; 65:718–728. [PubMed: 9009335]
- Bicanic T, Meintjes G, Wood R, Hayes M, Rebe K, Bekker LG, Harrison T. Fungal burden, early fungicidal activity, and outcome in cryptococcal meningitis in antiretroviral-naive or antiretroviral-experienced patients treated with amphotericin B or fluconazole. *Clin Infect Dis*. 2007; 45:76–80. [PubMed: 17554704]
- Bicanic T, Wood R, Meintjes G, Rebe K, Brouwer A, Loyse A, Bekker LG, Jaffar S, Harrison T. High-dose amphotericin B with flucytosine for the treatment of cryptococcal meningitis in HIV-infected patients: a randomized trial. *Clin Infect Dis*. 2008; 47:123–130. [PubMed: 18505387]
- Bicanic T, Brouwer AE, Meintjes G, Rebe K, Limmathurotsakul D, Chierakul W, Teparrakkul P, Loyse A, White NJ, Wood R, Jaffar S, Harrison T. Relationship of cerebrospinal fluid pressure, fungal burden and outcome in patients with cryptococcal meningitis undergoing serial lumbar punctures. *Aids*. 2009; 23:701–706. [PubMed: 19279443]
- Burchard W, Schmidt M, Stockmayer WH. Information on Polydispersity and Branching from Combined Quasi-Elastic and Intergrated Scattering. *Macromolecules*. 1980; 13:1265–1272.
- Casadevall A, Mukherjee J, Scharff MD. Monoclonal antibody based ELISAs for cryptococcal polysaccharide. *J Immunol Methods*. 1992; 154:27–35. [PubMed: 1401941]
- Chang Y, Kwon-Chung K. Complementation of a capsule-deficient mutation of *Cryptococcus neoformans* restores virulence. *MCB*. 1994; 14:4912–4919. [PubMed: 8007987]
- Charlier C, Chretien F, Baudrimont M, Mordelet E, Lortholary O, Dromer F. Capsule structure changes associated with *Cryptococcus neoformans* crossing of the blood-brain barrier. *Am J Pathol*. 2005; 166:421–432. [PubMed: 15681826]
- Cherniak R, Valafar H, Morris L, Valafar F. *Cryptococcus neoformans* Chemotyping by quantitative analysis of <sup>1</sup>H nuclear magnetic resonance spectra of glucuronoxylomannans with a computer-simulated artificial neural network. *Clinical and Diagnostic Laboratory Immunology*. 1998; 5:146–159. [PubMed: 9521136]
- Choi JN, Kim J, Kim J, Jung WH, Lee CH. Influence of Iron Regulation on the Metabolome of *Cryptococcus neoformans*. *PLoS One*. 2012; 7:e41654. [PubMed: 22911836]
- Cordero RJ, Frases S, Guimaraes AJ, Rivera J, Casadevall A. Evidence for branching in cryptococcal capsular polysaccharides and consequences on its biological activity. *Mol Microbiol*. 2011; 79:1101–1117. [PubMed: 21208301]
- Doering TL. How sweet it is! Cell wall biogenesis and polysaccharide capsule formation in *Cryptococcus neoformans*. *Annu Rev Microbiol*. 2009; 63:223–247. [PubMed: 19575556]
- Dromer F, Mathoulin-Pelissier S, Launay O, Lortholary O. Determinants of disease presentation and outcome during cryptococcosis: the CryptoA/D study. *PLoS Med*. 2007; 4:e21. [PubMed: 17284154]


- Fonseca FL, Nohara LL, Cordero RJ, Frases S, Casadevall A, Almeida IC, Nimrichter L, Rodrigues ML. Immunomodulatory effects of serotype B glucuronoxylomannan from *Cryptococcus gattii* correlate with polysaccharide diameter. *Infect Immun*. 2010; 78:3861–3870. [PubMed: 20547742]
- Frases S, Nimrichter L, Viana NB, Nakouzi A, Casadevall A. *Cryptococcus neoformans* capsular polysaccharide and exopolysaccharide fractions manifest physical, chemical, and antigenic differences. *Eukaryot Cell*. 2008; 7:319–327. [PubMed: 18156290]
- Frases S, Pontes B, Nimrichter L, Viana NB, Rodrigues ML, Casadevall A. Capsule of *Cryptococcus neoformans* grows by enlargement of polysaccharide molecules. *Proc Natl Acad Sci U S A*. 2009; 106:1228–1233. [PubMed: 19164571]
- Fries BC, Taborda CP, Serfass E, Casadevall A. Phenotypic switching of *Cryptococcus neoformans* occurs in vivo and influences the outcome of infection. *J Clin Invest*. 2001; 108:1639–1648. [PubMed: 11733559]
- Fries BC, Lee SC, Kennan R, Zhao W, Casadevall A, Goldman DL. Phenotypic switching of *Cryptococcus neoformans* can produce variants that elicit increased intracranial pressure in a rat model of cryptococcal meningoencephalitis. *Infect Immun*. 2005; 73:1779–1787. [PubMed: 15731079]
- Gates MA, Kozel TR. Differential localization of complement component 3 within the capsular matrix of *Cryptococcus neoformans*. *Infect Immun*. 2006; 74:3096–3106. [PubMed: 16714537]
- Goldman DL, Casadevall A, Zuckier LS. Pharmacokinetics and biodistribution of a monoclonal antibody to *Cryptococcus neoformans* capsular polysaccharide antigen in a rat model of cryptococcal meningitis: implications for passive immunotherapy. *J Med Vet Mycol*. 1997; 35:271–278. [PubMed: 9292424]
- Granger DL, Perfect JR, Durack DT. Virulence of *Cryptococcus neoformans*. Regulation of capsule synthesis by carbon dioxide. *J Clin Invest*. 1985; 76:508–516. [PubMed: 3928681]
- Graybill JR, Sobel J, Saag M, van Der Horst C, Powderly W, Cloud G, Riser L, Hamill R, Dismukes W. Diagnosis and management of increased intracranial pressure in patients with AIDS and cryptococcal meningitis. The NIAID Mycoses Study Group and AIDS Cooperative Treatment Groups. *Clin Infect Dis*. 2000; 30:47–54. [PubMed: 10619732]
- Guerrero A, Fries BC. Phenotypic switching in *Cryptococcus neoformans* contributes to virulence by changing the immunological host response. *Infect Immun*. 2008; 76:4322–4331. [PubMed: 18591227]
- Guerrero A, Jain N, Wang X, Fries BC. *Cryptococcus neoformans* variants generated by phenotypic switching differ in virulence through effects on macrophage activation. *Infect Immun*. 2010; 78:1049–1057. [PubMed: 20048044]
- Guimaraes AJ, Frases S, Cordero RJ, Nimrichter L, Casadevall A, Nosanchuk JD. *Cryptococcus neoformans* responds to mannitol by increasing capsule size in vitro and in vivo. *Cell Microbiol*. 2010; 12:740–753. [PubMed: 20070311]
- Haynes BC, Skowrya ML, Spencer SJ, Gish SR, Williams M, Held EP, Brent MR, Doering TL. Toward an integrated model of capsule regulation in *Cryptococcus neoformans*. *PLoS Pathog*. 2011; 7:e1002411. [PubMed: 22174677]
- Imwidthaya P, Pongvarin N. Cryptococcosis in AIDS. *Postgrad Med J*. 2000; 76:85–88. [PubMed: 10644384]
- Jain N, Cook E, Xess I, Hasan F, Fries D, Fries BC. Isolation and characterization of senescent *C. neoformans* and its implications for phenotypic switching and the pathogenesis of chronic cryptococcosis. *Eukaryot Cell*. 2009a; 8:858–866. [PubMed: 19411622]
- Jain N, Li L, Hsueh YP, Guerrero A, Heitman J, Goldman DL, Fries BC. Loss of allergen 1 confers a hypervirulent phenotype that resembles mucoid switch variants of *Cryptococcus neoformans*. *Infect Immun*. 2009b; 77:128–140. [PubMed: 18955480]
- Jung WH, Sham A, White R, Kronstad JW. Iron regulation of the major virulence factors in the AIDS-associated pathogen *Cryptococcus neoformans*. *PLoS Biol*. 2006; 4:e410. [PubMed: 17121456]
- Jung WH, Saikia S, Hu G, Wang J, Fung CK, D'Souza C, White R, Kronstad JW. HapX positively and negatively regulates the transcriptional response to iron deprivation in *Cryptococcus neoformans*. *PLoS Pathog*. 2010; 6:e1001209. [PubMed: 21124817]

- Kambugu A, Meya DB, Rhein J, O'Brien M, Janoff EN, Ronald AR, Kanya MR, Mayanja-Kizza H, Sande MA, Bohjanen PR, Boulware DR. Outcomes of cryptococcal meningitis in Uganda before and after the availability of highly active antiretroviral therapy. *Clin Infect Dis*. 2008; 46:1694–1701. [PubMed: 18433339]
- Lian T, Simmer MI, D'Souza CA, Steen BR, Zuyderduyn SD, Jones SJ, Marra MA, Kronstad JW. Iron-regulated transcription and capsule formation in the fungal pathogen *Cryptococcus neoformans*. *Mol Microbiol*. 2005; 55:1452–1472. [PubMed: 15720553]
- McClelland EE, Bernhardt P, Casadevall A. Coping with multiple virulence factors: which is most important? *PLoS Pathog*. 2005; 1:e40. [PubMed: 16738705]
- McFadden DC, De Jesus M, Casadevall A. The physical properties of the capsular polysaccharides from *Cryptococcus neoformans* suggest features for capsule construction. *J Biol Chem*. 2006; 281:1868–1875. [PubMed: 16278213]
- McFadden DC, Fries BC, Wang F, Casadevall A. Capsule structural heterogeneity and antigenic variation in *Cryptococcus neoformans*. *Eukaryot Cell*. 2007; 6:1464–1473. [PubMed: 17601878]
- Nimrichter L, Frases S, Cinelli LP, Viana NB, Nakouzi A, Travassos LR, Casadevall A, Rodrigues ML. Self-aggregation of *Cryptococcus neoformans* capsular glucuronoxylomannan is dependent on divalent cations. *Eukaryot Cell*. 2007; 6:1400–1410. [PubMed: 17573547]
- Nyhus KJ, Wilborn AT, Jacobson ES. Ferric iron reduction by *Cryptococcus neoformans*. *Infect Immun*. 1997; 65:434–438. [PubMed: 9009293]
- Oliveira DL, Nimrichter L, Miranda K, Frases S, Faull KF, Casadevall A, Rodrigues ML. *Cryptococcus neoformans* cryoultramicrotomy and vesicle fractionation reveals an intimate association between membrane lipids and glucuronoxylomannan. *Fungal genetics and biology : FG & B*. 2009; 46:956–963.
- Ory JJ, Griffith CL, Doering TL. An efficiently regulated promoter system for *Cryptococcus neoformans* utilizing the CTR4 promoter. *Yeast*. 2004; 21:919–926. [PubMed: 15334556]
- Park BJ, Wannemuehler KA, Marston BJ, Govender N, Pappas PG, Chiller TM. Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. *AIDS*. 2009; 23:525–530. [PubMed: 19182676]
- Perfect JR, Lang SD, Durack DT. Chronic cryptococcal meningitis: a new experimental model in rabbits. *Am J Pathol*. 1980; 101:177–194. [PubMed: 7004196]
- Pirofski LA, Casadevall A. The damage-response framework of microbial pathogenesis and infectious diseases. *Adv Exp Med Biol*. 2008; 635:135–146. [PubMed: 18841709]
- Rodrigues ML, Nimrichter L, Oliveira DL, Frases S, Miranda K, Zaragoza O, Alvarez M, Nakouzi A, Feldmesser M, Casadevall A. Vesicular polysaccharide export in *Cryptococcus neoformans* is a eukaryotic solution to the problem of fungal trans-cell wall transport. *Eukaryot Cell*. 2007; 6:48–59. [PubMed: 17114598]
- Rodrigues ML, Nakayasu ES, Oliveira DL, Nimrichter L, Nosanchuk JD, Almeida IC, Casadevall A. Extracellular vesicles produced by *Cryptococcus neoformans* contain protein components associated with virulence. *Eukaryot Cell*. 2008; 7:58–67. [PubMed: 18039940]
- Seaton RA, Naraqi S, Wembri JP, Warrell DA. Predictors of outcome in *Cryptococcus neoformans* var. *gattii* meningitis. *QJM*. 1996; 89:423–428. [PubMed: 8758045]
- Yoneda A, Doering TL. Regulation of *Cryptococcus neoformans* capsule size is mediated at the polymer level. *Eukaryot Cell*. 2008; 7:546–549. [PubMed: 18156288]
- Zaragoza O, Rodrigues ML, De Jesus M, Frases S, Dadachova E, Casadevall A. The capsule of the fungal pathogen *Cryptococcus neoformans*. *Adv Appl Microbiol*. 2009; 68:133–216. [PubMed: 19426855]



**Figure 1. Impaired capsule induction and differences in PS shedding and viscosity upon loss of *ALL1***


(A) H99- $\Delta all1$  mutant showed an impaired capsule induction defect after 24 h *in vivo* growth. Exo-PS concentrations from supernatants of *in vitro* cultures of RC2-wt (B) and H99-wt (C) was determined by ELISA after 1, 3, 6, 12 days, and 5, 9, 13, and 20 days of growth, respectively. (D) Intrinsic viscosities of exo-PSs from RC2-SM, RC2- $\Delta all1$ , RC2- $\Delta all1$  + *ALL1*, RC2-MC and (E) of exo-PS from H99-wt, and H99- $\Delta all1$ , H99- $\Delta all1$  + *ALL1*.



**Figure 2. Hydrodynamic size distribution of PS samples determined by DLS**

Hydrodynamic size distribution of exo-PS derived from wt, mutant and reconstituted strains was plotted as percentage of light scattering intensity versus effective diameter. Data are averages of 10 repeated measurements. All exo-PS solutions exhibited significant polydispersity. Note the polymer size difference reverted to wt in the reconstituted strains.






**Figure 3. Loss of Allergen1 produces PS with decreased mAb reactivity**


(A) ELISA of exo-PS isolated from wt and  $\Delta all1$  of RC2 and H99 background strains using anti-GXM mAbs 12A1, 21D2, and 13F1. For all mAbs tested,  $\Delta all1$  derived exo-PS showed lower reactivity. (B) Immunofluorescence micrograph of RC2-wt and RC2- $\Delta all1$  cells using mAb 12A1 directly conjugated to Alexa488. RC2- $\Delta all1$  cells showed a significant reduction in 12A1 binding to the capsule. Scale bar represents 10  $\mu$ m. (C) Complement-mediated phagocytosis of RC2-SM, RC2- $\Delta all1$ , RC2- $\Delta all1 + ALL1$ , H99-wt and H99- $\Delta all1$  and H99- $\Delta all1 + ALL1$ . A significant reduction in percentage of phagocytosis was observed for  $\Delta all1$  mutants relative to the parental and reconstituted strains in both serotypes. Data are

mean  $\pm$  SE of 4 independent experiments of triplicate wells. **(D)** Exo-PS from wt,  $\Delta all1$  and  $\Delta all1 + ALL1$  strains were added to the wt wells and similar percent reduction of phagocytosis values were observed when exo-PS from, respective  $\Delta all1$  mutant was added to SM-wt and H99-wtduring phagocytosis assay.



**Figure 4. *ALL1* indirectly regulate genes required for Iron-transport**

Differential gene expression in wild type (RC2-wt, H99-wt) and their respective  $\Delta all1$  mutants (RC2- $\Delta all1$ , H99- $\Delta all1$ ) were confirmed by real time PCR with selected iron-related genes, Real-time PCR results on RC2-wt, RC2- $\Delta all1$  (A) and H99-wt, H99- $\Delta all1$  (B) are shown. Black bars represents genes up-regulated in mutants. Bars represent average  $\pm$  SD mRNA ratios. The mRNA levels were normalized against the respective  $\beta$ -actin expression. Fold expression was calculated using the delta-delta CT method.



**Figure 5. Mutant of *ALL1* accumulates Intracellular iron and exo-PS affects the regulation of iron transport related genes**

Iron concentration was altered for RC2-SM, RC2- $\Delta all1$ , H99-wt, H99- $\Delta all1$  and reconstituted strains under low iron conditions (A, B) and in response to ferric chloride (C, D). Differences in exo-PS structure of H99-wt and H99- $\Delta all1$  mutant affect expression of iron transport related genes. *FTR1*, *FRE1*, *CNM02430*, *CNM02420*, *CNH01230*, *CNG00950*, *CIG1*, and *CNB00400* were up-regulated in H99- $\Delta all1$  (black bars) and in H99-wt cells (white bars) by addition of 40μg/ml mutant exo-PS. In contrast, addition of H99-wt exo-PS to H99- $\Delta all1$  cells (striped bars) resulted in significant down-regulation of iron transport related genes (E).

**Table 1**  
Macromolecular parameters of PS samples determined by static and dynamic light scattering analysis

Strain	$M_w$ ( $\times 10^6$ )	$R_g$ (nm)	$R_h$ (nm)	PDI	Mass Density ( $\times 10^4$ )	$\rho$
RC2 (SM)	1.66 $\pm$ 0.24	116.0 $\pm$ 9.7	266.4 $\pm$ 17.3	0.434 $\pm$ 0.013	1.43	0.43
RC2- <i>ΔallI</i>	0.89 $\pm$ 0.07	104.0 $\pm$ 4.3	121.4 $\pm$ 5.3	0.464 $\pm$ 0.015	0.83	0.86
RC2- <i>ΔallI</i> + <i>ALLI</i>	0.54 $\pm$ 0.03	116.3 $\pm$ 6.6	240.3 $\pm$ 25.9	0.452 $\pm$ 0.022	0.46	0.48
RC2 (MC)	1.80 $\pm$ 0.90	182.0 $\pm$ 10.7	238.2 $\pm$ 6.4	0.381 $\pm$ 0.026	0.99	0.76
H99-wt	7.07 $\pm$ 0.65	170.2 $\pm$ 6.3	353.8 $\pm$ 23.7	0.445 $\pm$ 0.015	4.15	0.48
H99- <i>ΔallI</i>	1.26 $\pm$ 0.06	142.4 $\pm$ 3.3	162.9 $\pm$ 10.5	0.377 $\pm$ 0.009	0.88	0.87
H99- <i>ΔallI</i> + <i>ALLI</i>	6.15 $\pm$ 0.58	168.0 $\pm$ 10.0	315.5 $\pm$ 15.7	0.461 $\pm$ 0.004	3.66	0.53

The average-molecular mass,  $M_w$  ( $\text{g mol}^{-1}$ ), radius of gyration,  $R_g$  (nm), hydrodynamic radius,  $R_h$  (nm), polydispersity index (PDI), average mass density ( $\text{g mol}^{-1} \text{nm}^{-1}$ ) and shape factor ( $\rho$ ) of *exo*-PS samples.  $M_w$ ,  $R_g$  data are represented as mean  $\pm$  SD of 2 measurements.  $R_h$  and polydispersity values are means  $\pm$  SE of 10 measurements.

**Table 2***ALL1* regulates genes required for Iron transport

Gene ID and Accession number	Fold Change
	RC2-SM vs RC2- $\Delta all1$
<i>CIG1</i> , cytokine inducing-glycoprotein; CNC01660	19.7
Ferric-chelate reductase activity; CNG00110	15.87
High-affinity iron permease, <i>FTRI</i> ; CNC05700	6.52
<i>FRE1</i> , ferroxidase; CNC05690	5.94
Hypothetical protein; CNK02840	3.94
Metalloreductase, ferric-chelate reductase activity; CNG00950	2.72
Zinc-Finger protein putative; CNI01980	2.65
Iron ion transmembrane transporter activity; CNM02430	2.57
Siderophore-iron uptake transmembrane transporter activity; CNG00120	2.48
Cytochrome-b5 reductase; CNB02540	2.35
Acidic laccase, putative; CNM02420	2.1
Siderophore-iron transmembrane transporter activity; CNB00400	2.0
Cytochrome b2, Mitochondrial Precursor; CNH01230	3.29

**Table 3**

GO terms identified in the differentially expressed genes

<b>GO Term and Identification number</b>	<b><i>p</i>-value</b>
Oxidoreductase activity, GO:0016491	$3.97 \times 10^{-5}$
Oxidation-reduction process, GO:0055114	$2.86 \times 10^{-4}$
Transmembrane transport, GO:0055085	$4.11 \times 10^{-4}$

**Table 4**

Strains used in this study

<b>Strain</b>	<b>Additional information</b>	<b>Reference</b>
RC2-SM	Serotype D, Switch variant Mat $\alpha$	(Fries <i>et al.</i> , 2001)
RC2-MC	Serotype D, Switch variant Mat $\alpha$	(Fries <i>et al.</i> , 2001)
RC2- $\Delta all1$	$\Delta all1$ : :NEO	(Jain <i>et al.</i> , 2009b)
RC2- $\Delta all1 + ALL1$	<i>ALL1</i> -NAT inserted to $\Delta all1$ : :NEO	(Jain <i>et al.</i> , 2009b)
H99	Serotype A, Mat $\alpha$	(Perfect <i>et al.</i> , 1980)
H99- $\Delta all1$	$\Delta all1$ : :NEO in H99	This study
H99- $\Delta all1 + ALL1$	<i>ALL1</i> -NAT inserted to $\Delta all1$ : :NEO	This study
$P_{CTR4-2}$ - <i>ALL1</i>	<i>ALL1</i> under <i>CTR4</i> copper transport promoter	This study